Nachrichten zur Eli Lilly & Co. Aktie

The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa

Strong sector performers stand out as AAPL, LLY, and V gain traction through services, drug demand, and digital payment growth.…

Top Stock Reports for Apple, Eli Lilly & Visa

Apples strong Services growth, Eli Lillys GLP-1 momentum, and Visas digital expansion headline todays top stock reports.…

Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)

…

Down 44%, Should You Buy the Dip on Viking Therapeutics? @themotleyfool #stocks $VKTX $LLY $PFE $NVO $MTSR

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.…

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after…

Exclusive: Bill Gates, PAHO consider ways to bring weight-loss drugs to lower-income countries

The Gates Foundation and the Pan American Health Organization are both working on ways to make weight-loss drugs like Novo…

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) reached $855.35 at the closing of the latest trading day, reflecting a +1.14% change compared to its…

Lilly Endowment sells $137 million in Eli Lilly shares By Investing.com

Lilly Endowment sells $137 million in Eli Lilly shares…

Where Will LLY Be in 5 Years?

After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.…

Eli Lilly to invest more than $1B in India, Reuters reports

Eli Lilly (LLY) plans to invest more than $1B in India in the coming years to boost manufacturing and supply…

Eli Lilly Stock Rises 16% in a Week: Heres What You Should Know

LLY shares have jumped 16% last week as Pfizers landmark government deal boosted investor confidence across the pharma sector.…

Eli Lilly: Beyond Weight Loss

Eli Lilly is riding a big trend.…

Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through…

Eli Lilly (LLY) Laps the Stock Market: Heres Why

Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.…

Eli Lilly (LLY) Laps the Stock Market: Heres Why

Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.…

Why Shares of Eli Lilly Soared This Week

Pfizers deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.…

Hims & Hers Health (HIMS) Legal Relief Raises Fresh Questions About Its Long-Term Regulatory Risks

In the past week, a U.S. federal judge dismissed Eli Lillys lawsuit against Willow Health, a telehealth competitor to Hims…

Eli Lilly and Its Competitors Pop on the Pfizer News

Market Analysis by covering: Eli Lilly and Company, Merck & Company Inc, Pfizer Inc, AbbVie Inc. Read s Market…

agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after news of a new government prescription drug policy…

Insight: Trump administration targets deals in dozens of industries before midterms

Eli Lilly was asked to produce more insulin; Pfizer to produce more of its top-selling cancer drug Ibrance and its…

Stock Market Today: Nike, Eli Lily surge; Robinhood slips

Here are the stocks that made the biggest moves today.…

Eli Lilly, Merck Lead Market Cap Stock Movers on Wednesday By Investing.com

Eli Lilly, Merck Lead Market Cap Stock Movers on Wednesday…

Top Stock Movers Now: Nike, Eli Lilly, Corteva, AES, and More

Pharmaceutical stocks gained Wednesday afternoon amid anticipation Pfizers deal with the Trump administration could lead to more with other firms.…

Buy HIMS Stock At $56?

Earlier this year, Eli Lilly had initiated a lawsuit against Willow Health along with three other telehealth companies concerning the…

Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth

…

Are These GLP-1 Trial Results About to Send Eli Lillys Stock Soaring?

The pharmaceutical company had a clinical setback earlier this year, but thats now in the rearview mirror.…

LLY Gets EU Approval for Alzheimers Drug & FDA Nod to Cancer Therapy

Eli Lilly secures EU approval for Alzheimers drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.…

Eli Lilly: Buying The Dip With Confidence

…

Stock Movers: Eli Lilly, CarMax, Jabil

Bloomberg journalists discuss todays biggest winners and losers in the stock market. Listen for analysis on the companies making news…

LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?

Eli Lillys diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity…

Eli Lilly (LLY) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the…

Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs

More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries…

Celltrion unit pays $330 million for Eli Lilly production facility, filing shows

Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC…

Top Analyst Reports for Apple, Eli Lilly & Chevron

Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.…

Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity

…

Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts

Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according…

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment…

Heres Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today @themotleyfool #stocks $NVO $LLY

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling…

dpa-AFX ProFeed